{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:14Z","timestamp":1772165714588,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To determine the risk of cesarean delivery after labor induction among patients with prior placenta-mediated pregnancy complications (pre-eclampsia, late pregnancy loss, placental abruption or intrauterine growth restriction).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The AFFIRM database includes patient level data from 9 randomized controlled trials that evaluated the role of LMWH versus no LMWH during pregnancy to prevent recurrent placenta-mediated pregnancy complications. The primary outcome of this sub-study was the proportion of women who had an unplanned cesarean delivery after induction of labor compared to after spontaneous labor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 512 patients from 7 randomized trials included in our sub-study. There was no difference in the risk of cesarean delivery between women with labor induction (21\/148, 14.2%) and spontaneous labor (79\/364, 21.7%) (odds ratio (OR) 0.60, 95% CI, 0.35\u20131.01;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.052). Among 274 women who used LMWH prophylaxis during pregnancy, the risk of cesarean delivery was lower among those that underwent labor induction (9.8%) compared to spontaneous labor (22.4%) (OR 0.38, 95% CI, 0.17\u20130.84;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The risk of cesarean delivery is not increased after labor induction among a higher risk patient population with prior pregnancy complications. Our results suggest that women who receive LMWH during pregnancy might benefit from labor induction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-019-2615-x","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T12:02:44Z","timestamp":1575028964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The risk of cesarean delivery after labor induction among women with prior pregnancy complications: a subgroup analysis of the AFFIRM study"],"prefix":"10.1186","volume":"19","author":[{"name":"for the AFFIRM investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-398X","authenticated-orcid":false,"given":"Leslie","family":"Skeith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Le Gal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna I. P.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00ebtte","family":"Goddijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risto","family":"Kaaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Gris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Schleu\u00dfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Petroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Rodger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"2615_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1503\/cmaj.130925","volume":"186","author":"E Mishanina","year":"2014","unstructured":"Mishanina E, Rogozinska E, Thatthi T, Uddin-Khan R, Khan KS, Meads C. Use of labour induction and risk of cesarean delivery: a systematic review and meta-analysis. C Can Med Assoc J. 2014;186:665\u201373.","journal-title":"C Can Med Assoc J"},{"key":"2615_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.7326\/0003-4819-151-4-200908180-00007","volume":"151","author":"AB Caughey","year":"2009","unstructured":"Caughey AB, Sundaram V, Kaimal AJ, Gienger A. Systematic review: elective induction of labor versus expectant Management of Pregnancy. Ann Intern Med. 2009;151:252\u201363.","journal-title":"Ann Intern Med"},{"key":"2615_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/1471-0528.12328","volume":"121","author":"S Wood","year":"2014","unstructured":"Wood S, Cooper S, Ross S. Does induction of labour increase the risk of caesarean section? A systematic review and meta-analysis of trials in women with intact membranes. BJOG. 2014;121:674\u201385.","journal-title":"BJOG"},{"key":"2615_CR4","first-page":"1","volume":"176","author":"A Caughey","year":"2009","unstructured":"Caughey A, Sundaram V, Kaimal A, et al. Maternal and neonatal outcomes of elective induction of labor. Evid Rep Technol Assess. 2009;176:1\u2013257.","journal-title":"Evid Rep Technol Assess"},{"key":"2615_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/1471-0528.13682","volume":"123","author":"VA Danilack","year":"2016","unstructured":"Danilack VA, Dore DD, Triche EW, Muri JH, Phipps MG. The effect of labour induction on the risk of caesarean delivery: using propensity scores to control confounding by indication. BJOG. 2016;123:1521\u20139.","journal-title":"BJOG"},{"key":"2615_CR6","first-page":"1","volume":"0","author":"I Parkes","year":"2014","unstructured":"Parkes I, Kabiri D, Hants Y, Ezra Y. The indication for induction of labor impacts the risk of cesarean delivery. J Matern Fetal Neonatal Med. 2014;0:1\u20135.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2615_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00404-016-4171-1","volume":"294","author":"R Gabbay-Benziv","year":"2016","unstructured":"Gabbay-Benziv R, Hadar E, Ashwal E, Chen R, Wiznitzer A, Hiersch L. Induction of labor: does indication matter? Arch Gynecol Obstet. 2016;294:1195\u2013201.","journal-title":"Arch Gynecol Obstet"},{"key":"2615_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa1509117","volume":"374","author":"N Grace","year":"2016","unstructured":"Grace N, Wildsmith C, Bradshaw L, Sc M, Smith GCS, Sc D. Randomized trial of labor induction in women 35 years of age or older. N Engl J Med. 2016;374:813\u201322.","journal-title":"N Engl J Med"},{"key":"2615_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/1471-0528.14389","volume":"124","author":"S Alberico","year":"2016","unstructured":"Alberico S, Erenbourg A, Hod M, et al. Immediate delivery or expectant management in gestational diabetes at term: the GINEXMAL randomised controlled trial. BJOG. 2016;124:669\u201377.","journal-title":"BJOG"},{"key":"2615_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1800566","volume":"379","author":"WA Grobman","year":"2018","unstructured":"Grobman WA, Rice MM, Reddy UM, et al. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med. 2018;379:513\u201323.","journal-title":"N Engl J Med"},{"key":"2615_CR11","doi-asserted-by":"crossref","unstructured":"Grobman WA, Rice MM, Reddy UM, et al. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med. 2018;379:513-23.","DOI":"10.1056\/NEJMoa1800566"},{"key":"2615_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0140-6736(09)60736-4","volume":"374","author":"CM Koopmans","year":"2009","unstructured":"Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks\u2019 gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374:979\u201388.","journal-title":"Lancet"},{"key":"2615_CR13","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/1471-0528.14028","volume":"123","author":"TP Bernardes","year":"2016","unstructured":"Bernardes TP, Broekhuijsen K, Koopmans CM, et al. Caesarean section rates and adverse neonatal outcomes after induction of labour versus expectant management in women with an unripe cervix: a secondary analysis of the HYPITAT and DIGITAT trials. BJOG An Int J Obstet Gynaecol. 2016;123:1501\u20138.","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"2615_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/jp.2017.31","volume":"37","author":"C Roland","year":"2017","unstructured":"Roland C, Warshak CR, Defranco EA, Roland C. Success of labor induction for pre-eclampsia at preterm and term gestational ages. J Perinatol. 2017;37:636\u201340.","journal-title":"J Perinatol"},{"key":"2615_CR15","volume":"1","author":"C Cluver","year":"2017","unstructured":"Cluver C, Novikova N, Cm K, et al. Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term. Cochrane Libr. 2017;1:CD009273.","journal-title":"Cochrane Libr"},{"key":"2615_CR16","unstructured":"Ram M, Berger H, Geary M, et al. Timing of delivery in women With chronic hypertension. Obstet Gynecol. 2018; Epub online 15 June 2018."},{"key":"2615_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/1471-0528.14906","volume":"125","author":"E Malacova","year":"2018","unstructured":"Malacova E, Regan A, Nassar N, et al. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis. BJOG. 2018;125:183\u201392.","journal-title":"BJOG"},{"key":"2615_CR18","first-page":"1","volume":"296","author":"D Leduc","year":"2013","unstructured":"Leduc D, Biringer A, Lee L, Dy J. SOGC clinical practice guideline: induction of labour. SOGC Clin Pract Guidel. 2013;296:1\u201318.","journal-title":"SOGC Clin Pract Guidel"},{"key":"2615_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11239-015-1309-0","volume":"41","author":"SM Bates","year":"2016","unstructured":"Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:92\u2013128.","journal-title":"J Thromb Thrombolysis"},{"key":"2615_CR20","first-page":"1","volume":"6736","author":"MA Rodger","year":"2016","unstructured":"Rodger MA, Gris J, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016;6736:1\u201313.","journal-title":"Lancet"},{"key":"2615_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/2046-4053-3-69","volume":"3","author":"MA Rodger","year":"2014","unstructured":"Rodger MA, Langlois NJ, de Vries JI, et al. Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). Syst Rev. 2014;3:69.","journal-title":"Syst Rev"},{"key":"2615_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"2615_CR23","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(14)60793-5","volume":"384","author":"MA Rodger","year":"2014","unstructured":"Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384:1673\u201383.","journal-title":"Lancet"},{"key":"2615_CR24","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJMoa1000641","volume":"362","author":"SP Kaandorp","year":"2010","unstructured":"Kaandorp SP, Goddijn M, van Der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362:1586\u201396.","journal-title":"N Engl J Med"},{"key":"2615_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1160\/TH10-05-0334","volume":"105","author":"J Visser","year":"2011","unstructured":"Visser J, Ulander VM, Helmerhorst FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia - HABENOX: a randomised multicentre trial. Thromb Haemost. 2011;105:295\u2013301.","journal-title":"Thromb Haemost"},{"key":"2615_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1160\/TH10-03-0167","volume":"104","author":"JC Gris","year":"2010","unstructured":"Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae: the pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010;104:771\u20139.","journal-title":"Thromb Haemost"},{"key":"2615_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1160\/TH11-05-0340","volume":"106","author":"JC Gris","year":"2011","unstructured":"Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: the pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011;106:1053\u201361.","journal-title":"Thromb Haemost"},{"key":"2615_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/j.1538-7836.2012.04706.x","volume":"10","author":"JIP de Vries","year":"2012","unstructured":"de Vries JIP, Hague WM, van Pampus MG. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10:1196.","journal-title":"J Thromb Haemost"},{"key":"2615_CR29","first-page":"3269","volume":"119","author":"I Martinelli","year":"2012","unstructured":"Martinelli I, Ruggenenti P, Cetin I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications. Prospective , Randomized , Multicenter , Control Clin Trial. 2012;119:3269\u201375.","journal-title":"Prospective , Randomized , Multicenter , Control Clin Trial"},{"key":"2615_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.7326\/M14-2062","volume":"162","author":"E Schleussner","year":"2015","unstructured":"Schleussner E, Kamin G, Seliger G, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss a multicenter trial with a minimization randomization scheme. Ann Intern Med. 2015;162:601\u20139.","journal-title":"Ann Intern Med"},{"key":"2615_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1538-7836.2008.03230.x","volume":"7","author":"E Rey","year":"2009","unstructured":"Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7:58\u201364.","journal-title":"J Thromb Haemost"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-019-2615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12884-019-2615-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-019-2615-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T19:22:23Z","timestamp":1606504943000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-019-2615-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2615"],"URL":"https:\/\/doi.org\/10.1186\/s12884-019-2615-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11596\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11596\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11596\/v2","asserted-by":"object"}]},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"19 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained for each trial before recoding and combining the data in the AFFIRM database [\n                      \n                      ]. The Ottawa Health Science Network Research Ethics Board (OHSN-REB) approved this sub-study to access and use the data analysed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.S. has received honoraria and non-financial research support from Leo Pharma, and has received grant funding from CSL-Behring. L.S. received a Fellowship Award from the CanVECTOR Network. G.L.G. has received honoraria from Bayer Inc., Pfizer, LEO Pharma, Sanofi biomerieux, and research support as a co-investigator for clinical trials from Portola Pharmaceuticals, Boehringer-Ingelheim, Pfizer, Bristol-Myers Squibb, LEO Pharma, Daiichi Sankyo, Bayer Inc. G.L.G. holds an Early Researcher Award from the Province of Ontario, a CP Has Heart Cardiovascular Award, and the Chair on Diagnosis of Venous Thromboembolism from the Department of Medicine, University of Ottawa.J.I.P.dV. has received grant funding from Pfizer. S.M. has received Grant or Research Support from Aspen, BMS\/Pfizer, Sanquin, Daiichi Sankyo and Bayer, Consultant fees from Bayer, BMS\/Pfizer, Boehringer Ingelheim and Daiichi Sankyo, Portola and Sanofi. S.M. holds a VIDI Innovative Grant from the Netherlands Organisation for Health Research and Development (NWO, 2012) on Thrombophilia and Reproduction. M.G. No competing financial interests. R.K. no competing financial interests. J-C.G. no competing financial interests. I.M. No competing financial interests. E.S. received grant funding from Pfizer Pharma GmbH Germany. D.P. No competing financial interests. N.L. No competing financial interests. M.A.R. No competing financial interests. M.A.R. is supported by Heart and Stroke Foundation Career Investigator Awards (CI6225 and CI7441) and a University of Ottawa Faculty of Medicine Clinical Research Chair in Venous Thrombosis and Thrombophilia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"455"}}